UK patients who carry epinephrine (adrenaline) 300µg auto-injector pens (Emerade) [1](#Fn1){ref-type="fn"} should contact their prescriber to seek a replacement product, advises the UK\'s MHRA.

The regulatory agency recently notified healthcare professionals of a recall of these Emerade auto-injector pens pens, which \"*is due to reports of difficulty in activating the pens, meaning the dose of adrenaline may not be delivered when needed by a patient for a severe, acute allergic reaction (anaphylaxis)*\", said the MHRA. This action followed a previous recall last month (4 March) of Emerade 150µg auto-injector pens.

In light of the current global COVID-19 pandemic, patients and/or caregivers should heed advice or guidance on social distancing from the MHRA or NHS, including:

make a phone appointment with their doctor requesting a prescription for replacement pens (i.e. two should always be carried at a time), and they should not visit the GP surgery unless advised by their doctor.request the prescription is sent to a pharmacy to avoid collecting in-person from the GP surgery.in the event a patient and/or their household is self-isolating, the replacement pens should be collected for patients by a friend or relative (some pharmacies may offer a home delivery service).once the patient has received their replacement auto-injector pens, the recalled Emerade 300µg pens can be returned to their pharmacy (some pharmacies may have drop-off boxes).

Two of the alternative brands of epinephrine auto-injector pens that will be available include EpiPen and Jext. The MHRA highlighted that \"*the manufacturers\' websites for each brand of pen have information and training videos on how to use a specific pen*\".

applies to Emerade 300µg pens that are still in-date and those that are due to expire.
